Trial reportEuropean journal of medical research2025
Effect of vitamin D status on a disintegrin-like and metalloprotease with thrombospondin type 1 motif 13 (ADAMTS13) and interleukin 6 in patients with acute myeloid leukaemia.
Trial report in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05149339 (Effect of Vitamin D Status on A Disintegrin-like And Metalloprotease With Thrombospondin Type 1 Motif 13), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Vitamin D Status on A Disintegrin-like And Metalloprotease With Thrombospondin Type 1 Motif 13 (ADAMTS13) and Interleukin 6 (IL-6) in Patients With Acute Myeloid Leukemia
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLow levels of the enzyme ADAMTS13 and elevated inflammatory markers such as interleukin-6 (IL-6) are associated with worse outcomes in patients with acute myeloid leukaemia (AML). IL-6 produced by leukaemia cells suppresses ADAMTS13 activity and impairs hematopoietic differentiation. Vitamin D, which has known for its immunomodulatory effects, may reduce IL-6 levels. This study investigated the impact of vitamin D supplementation on IL-6 and ADAMTS13 levels in patients newly diagnosed with AML. PATIENTS AND
methodA total of 38 newly diagnosed AML patients and 14 healthy individuals were included. IL-6 and ADAMTS13 levels were measured in both groups at baseline. Among AML patients, 34 were found to have vitamin D deficiency. Seventeen of these patients received oral vitamin D supplementation for 28 days in addition to their standard chemotherapy. Serum levels of IL-6, ADAMTS13 and vitamin D were measured on the 1st and 28th days of chemotherapy. Statistical analyses included Mann-Whitney U test, Wilcoxon signed-rank test, and Spearman correlation.
resultsAML patients had significantly higher IL-6 (7.19 vs. 1.15 pg/mL; p = 0.00001) and lower ADAMTS13 (684 vs. 1205 ng/mL; p = 0.001) compared to controls. ADAMTS13 significantly increased by Day 28 (p = 0.0001), while IL-6 showed no overall change. However, among vitamin D-deficient patients receiving supplementation, IL-6 levels decreased significantly by Day 28 (p = 0.049). A negative correlation was found between vitamin D and IL-6 on Day 28 (r = -0.485; p = 0.035). No significant effect of vitamin D status was observed on ADAMTS13 levels.
conclusionVitamin D supplementation was associated with a reduction in IL-6 levels, but did not influence ADAMTS13 levels in patients with AML. These findings support the potential role of vitamin D as an adjunct anti-inflammatory agent during induction chemotherapy. Further studies with larger samples and longer follow-up are recommended to clarify its therapeutic relevance. Trial registration number NCT05149339 in www. CLINICALTRIAL: gov registered on 25/11/2021 'retrospectively registered' with URL; https://register. CLINICALTRIALS: gov/prs/app/action/SelectProtocol?sid=S000BKX8&selectaction=Edit&uid=U0005ZGQ&ts=98&cx=avh64j .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.